Top

Published in:

01-06-2015 | Colorectal Cancer

Reirradiation Using Carbon Ions in Patients with Locally Recurrent Rectal Cancer at HIT: First Results

Authors: Daniel Habermehl, MD, Martin Wagner, MD, Malte Ellerbrock, PhD, Markus W. Büchler, MD, Oliver Jäkel, PhD, Jürgen Debus, MD, PhD, Stephanie E. Combs, MD

Published in: Annals of Surgical Oncology | Issue 6/2015

Abstract

Background

Locally recurrent rectal cancer remains a dreaded event because curative resection is unlikely to be performed in a large number of cases. Carbon ion radiotherapy offers physical and biologic advantages. A high precise local dose deposition and sparing of normal tissue is possible. This work summarizes our experience on feasibility and early toxicity of carbon ion radiotherapy in previously irradiated and operated patients.

Methods

Between 2010 and 2013, a total of 19 patients with a median age of 62 years (range 14–76 years) received carbon ion irradiation to treat locally recurrent rectal cancer at the Heidelberg Ion Beam Therapy Center (HIT). All patients had a history of surgery and pelvic radiotherapy of at least 50.4 Gy. Median dose was 36 Gy [relative biologic efficacy (RBE)] [range 36–51 Gy(RBE)], and median planning target volume was 456 ml (range 75–1,597 ml). Some patients were treated in the recruiting phase I/II of the PANDORA study (NCT01528683).

Results

Median follow-up was 7.8 months. Four patients were diagnosed with local relapse after carbon ion radiotherapy, and three patients developed distant metastases. Estimated mean local progression-free survival was 20.6 months by the Kaplan–Meier estimator. Two patients had preexisting rectovaginal fistula, and another patient had a preexisting presacral localized abscess formation in which the local relapse took place. No grade III or higher toxicities were observed.

Conclusions

Our first experiences in a pretreated patient group with a dismal prognosis are encouraging, and therapy-related side effects are mild. Longer follow-up is required to determine possible late effects and long-term disease control.

National Comprehensive Cancer Network. Rectal cancer, version 3.2014. Available at: http://nccn.org.

Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926–33. CrossRefPubMed

De Caluwe L, Van Nieuwenhove Y, Ceelen WP. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev. 2013;2:CD006041.PubMed

Ngan SY, Burmeister B, Fisher RJ, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012;30:3827–33.CrossRefPubMed

Yu TK, Bhosale PR, Crane CH, et al. Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2008;71:1175–80.CrossRefPubMed

Calvo FA, Sole CV, Alvarez de Sierra P, et al. Prognostic impact of external beam radiation therapy in patients treated with and without extended surgery and intraoperative electrons for locally recurrent rectal cancer: 16-year experience in a single institution. Int J Radiat Oncol Biol Phys. 2013;86:892–900.CrossRefPubMed

Alberda WJ, Verhoef C, Nuyttens JJ, et al. Outcome in patients with resectable locally recurrent rectal cancer after total mesorectal excision with and without previous neoadjuvant radiotherapy for the primary rectal tumor. Ann Surg Oncol. 2014;21(2):520–6.

Combs SE, Kalbe A, Nikoghosyan A, et al. Carbon ion radiotherapy performed as re-irradiation using active beam delivery in patients with tumors of the brain, skull base and sacral region. Radiother Oncol. 2011;98:63–7.CrossRefPubMed

Rieken S, Habermehl D, Haberer T, Jaekel O, Debus J, Combs SE. Proton and carbon ion radiotherapy for primary brain tumors delivered with active raster scanning at the Heidelberg Ion Therapy Center (HIT): early treatment results and study concepts. Radiat Oncol. 2012;7:41.CrossRefPubMedCentralPubMed

10.

Combs SE, Ellerbrock M, Haberer T, et al. Heidelberg Ion Therapy Center (HIT): initial clinical experience in the first 80 patients. Acta Oncol. 2010;49:1132–40.CrossRefPubMed

11.

Schulz-Ertner D, Jakel O, Schlegel W. Radiation therapy with charged particles. Semin Radiat Oncol. 2006;16:249–59.CrossRefPubMed

12.

Tsujii H, Mizoe JE, Kamada T, et al. Overview of clinical experiences on carbon ion radiotherapy at NIRS. Radiother Oncol. 2004;73(Suppl 2):S41–9.CrossRefPubMed

13.

Yamada S, Shinoto M, Shigeo Y, et al. [Current status and perspective of heavy ion beam therapy for patients with pelvic recurrence after primarily resected rectal cancer]. Gan To Kagaku Ryoho. 2009;36:1263–6.PubMed

14.

Koizumi M, Saga T, Yoshikawa K, et al. ¹¹C-methionine-PET for evaluation of carbon ion radiotherapy in patients with pelvic recurrence of rectal cancer. Mol Imaging Biol. 2008;10:374–80.CrossRefPubMed

15.

Combs SE, Kieser M, Habermehl D, et al. Phase I/II trial evaluating carbon ion radiotherapy for the treatment of recurrent rectal cancer: the PANDORA-01 trial. BMC Cancer. 2012;12:137.CrossRefPubMedCentralPubMed

16.

Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109–22.CrossRefPubMed

17.

Scholz M, Kellerer AM, Kraft-Weyrather W, Kraft G. Computation of cell survival in heavy ion beams for therapy. The model and its approximation. Radiat Environ Biophys. 1997;36:59–66.CrossRefPubMed

18.

Adeberg S, Baris D, Habermehl D, et al. Evaluation of radiochemotherapy with carbon ions and the influence of p53 mutational status in the colorectal carcinoma cell line HCT 116. In: Strahlentherapie und Onkologie. Munich, Germany: Urban & Vogel; 2012. pp. 136–7.

19.

Habermehl D, Debus J, Ganten T, et al. Hypofractionated carbon ion therapy delivered with scanned ion beams for patients with hepatocellular carcinoma—feasibility and clinical response. Radiat Oncol. 2013;8:59.CrossRefPubMedCentralPubMed

20.

Schulz-Ertner D, Nikoghosyan A, Thilmann C, et al. Results of carbon ion radiotherapy in 152 patients. Int J Radiat Oncol Biol Phys. 2004;58:631–40.CrossRefPubMed

21.

Das P, Delclos ME, Skibber JM, et al. Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation. Int J Radiat Oncol Biol Phys. 2010;77:60–5.CrossRefPubMed

22.

Valentini V, Morganti AG, Gambacorta MA, et al. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: a multicentric phase II study. Int J Radiat Oncol Biol Phys. 2006;64:1129–39.CrossRefPubMed

23.

Sun DS, Zhang JD, Li L, Dai Y, Yu JM, Shao ZY. Accelerated hyperfractionation field-involved re-irradiation combined with concurrent capecitabine chemotherapy for locally recurrent and irresectable rectal cancer. Br J Radiol. 2012;85:259–64.CrossRefPubMedCentralPubMed

24.

Gillmann C, Jakel O, Schlampp I, Karger CP. Temporal lobe reactions after carbon ion radiation therapy: comparison of relative biological effectiveness-weighted tolerance doses predicted by local effect models I and IV. Int J Radiat Oncol Biol Phys. 2014;88:1136–41.CrossRefPubMed

25.

Friedrich T, Grun R, Scholz U, Elsasser T, Durante M, Scholz M. Sensitivity analysis of the relative biological effectiveness predicted by the local effect model. Phys Med Biol. 2013;58:6827–49.CrossRefPubMed

26.

Grun R, Friedrich T, Elsasser T, et al. Impact of enhancements in the local effect model (LEM) on the predicted RBE-weighted target dose distribution in carbon ion therapy. Phys Med Biol. 2012;57:7261–74.CrossRefPubMed

27.

Jensen AD, Nikoghosyan AV, Ecker S, et al. Raster-scanned carbon ion therapy for malignant salivary gland tumors: acute toxicity and initial treatment response. Radiat Oncol. 2011;6:149.CrossRefPubMedCentralPubMed

28.

Uhl M, Mattke M, Welzel T, et al. High control rate in patients with chondrosarcoma of the skull base after carbon ion therapy: first report of long-term results. Cancer. 2014;120:1579–85.CrossRefPubMed

29.

Uhl M, Mattke M, Welzel T, et al. Highly effective treatment of skull base chordoma with carbon ion irradiation using a raster scan technique in 155 patients: first long-term results. Cancer. 2014;120(21):3410–7.

Title: Reirradiation Using Carbon Ions in Patients with Locally Recurrent Rectal Cancer at HIT: First Results
Authors: Daniel Habermehl, MD
Martin Wagner, MD
Malte Ellerbrock, PhD
Markus W. Büchler, MD
Oliver Jäkel, PhD
Jürgen Debus, MD, PhD
Stephanie E. Combs, MD
Publication date: 01-06-2015
Publisher: Springer US
Published in: Annals of Surgical Oncology / Issue 6/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-014-4219-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Reirradiation Using Carbon Ions in Patients with Locally Recurrent Rectal Cancer at HIT: First Results

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2015

Pathologic Complete Response to Intralesional Interleukin-2 Therapy Associated with Improved Survival in Melanoma Patients with In-Transit Disease

Thyroid Cancer Presentation and Treatment in the United States

Risk of Lymph Node Metastasis in Differentiated Type Mucosal Early Gastric Cancer Mixed with Minor Undifferentiated Type Histology

Local Recurrence in the Neck and Survival After Thyroidectomy for Metastatic Renal Cell Carcinoma

Melanoma of the Vulva and Vagina: Principles of Staging and Their Relevance to Management Based on a Clinicopathologic Analysis of 85 Cases

Palliative Care Training in Surgical Oncology and Hepatobiliary Fellowships: A National Survey of the Fellows